Analyzing Positron (POSC) and The Competition

Positron (OTCMKTS:POSC) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Positron to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.

Institutional and Insider Ownership

44.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 14.8% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Positron and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	270	803	2020	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,351.31%. Given Positron’s rivals higher probable upside, analysts clearly believe Positron has less favorable growth aspects than its rivals.

Profitability

This table compares Positron and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-331.31%	-92.24%	-30.04%

Valuation and Earnings

This table compares Positron and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-12.13
Positron Competitors	$1.00 billion	$85.30 million	5.55

Positron’s rivals have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Positron has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s rivals have a beta of 17.00, meaning that their average stock price is 1,600% more volatile than the S&P 500.

Summary

Positron rivals beat Positron on 7 of the 10 factors compared.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.